Radiosurgical boost for primary high-grade gliomas
The purpose of this study was to retrospectively evaluate the survival of patients with high-grade gliomas treated with external beam radiotherapy with or without radiosurgical boost. From July 1993 to April 1998, 32 patients were selected, 15 of which received radiosurgery. Inclusion criteria were...
Gespeichert in:
Veröffentlicht in: | Journal of neuro-oncology 2002-04, Vol.57 (2), p.151-160 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 160 |
---|---|
container_issue | 2 |
container_start_page | 151 |
container_title | Journal of neuro-oncology |
container_volume | 57 |
creator | PRISCO, Flavio E WELTMAN, Eduardo HANRIOT, Rodrigo De BRANDT, Reynaldo A |
description | The purpose of this study was to retrospectively evaluate the survival of patients with high-grade gliomas treated with external beam radiotherapy with or without radiosurgical boost. From July 1993 to April 1998, 32 patients were selected, 15 of which received radiosurgery. Inclusion criteria were age > 18 years, histological confirmation of high-grade glioma, primary tumor treatment with curative intent, unifocal tumor and supratentorial location. All patients were found to be in classes III-VI, according to the recursive partitioning analysis proposed by the Radiation Therapy Oncology Group. The median interval between radiotherapy and radiosurgery was 5 weeks (range 1-13). Treatment volumes ranged from 2.9 to 70.3 cc (median 15.0 cc). Prescribed radiosurgery doses varied from 8.0 to 12.5 Gy (median 10.0 Gy). Radiosurgery and control groups were well balanced with respect to prognostic factor distributions. Median actuarial survival time in radiosurgery and control groups was 21.4 months and 11.6 months, respectively (p = 0.0254). Among patients with KPS > 80, median survival time was 11.0 months and 53.9 months in the control and radiosurgery groups, respectively (p = 0.0103). Radiosurgery was the single factor correlated with survival on Cox model analysis (p = 0.0362) and was associated with a 2.76 relative reduction in the risk of cancer death (95% confidence interval (CI) 1.07-7.13). Our results suggest that radiosurgery may confer a survival advantage for patients in RPA classes III-VI, especially for those with Karnofsky performance status >80. The definitive role of radiosurgical boost for patients with high-grade gliomas awaits the results of randomized trials. |
doi_str_mv | 10.1023/A:1015757322379 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71927049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>390347881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-d44e2dec97079535b2727d36d31aa98038c5641965e2f8b3f24489c38c7162953</originalsourceid><addsrcrecordid>eNpd0N1LwzAQAPAgipvTZ9-kCPpWTe6SXuPbGH7BQBAF30rapl1Ht8xkffC_N2BF8Om443fH3TF2LviN4IC38zvBhSJFCICkD9g0ZpgSEh6yKRcZpUrLjwk7CWHNOZeE4phNBAhQmmjK4NXUnQuDb7vK9EnpXNgnjfPJzncb47-SVdeu0tab2iZt37mNCafsqDF9sGdjnLH3h_u3xVO6fHl8XsyXaYWC79NaSgu1rTRx0gpVCQRUY1ajMEbnHPNKZVLoTFlo8hIbkDLXVSyTyCB2zNj1z9ydd5-DDfti04XK9r3ZWjeEgoQG4lJHePkPrt3gt3G3AoRWlHEFEV2MaCg3ti7G-4rfV0RwNQIT4isab7ZVF_4cEgCXOX4D96dqKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219576052</pqid></control><display><type>article</type><title>Radiosurgical boost for primary high-grade gliomas</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>PRISCO, Flavio E ; WELTMAN, Eduardo ; HANRIOT, Rodrigo De ; BRANDT, Reynaldo A</creator><creatorcontrib>PRISCO, Flavio E ; WELTMAN, Eduardo ; HANRIOT, Rodrigo De ; BRANDT, Reynaldo A</creatorcontrib><description>The purpose of this study was to retrospectively evaluate the survival of patients with high-grade gliomas treated with external beam radiotherapy with or without radiosurgical boost. From July 1993 to April 1998, 32 patients were selected, 15 of which received radiosurgery. Inclusion criteria were age > 18 years, histological confirmation of high-grade glioma, primary tumor treatment with curative intent, unifocal tumor and supratentorial location. All patients were found to be in classes III-VI, according to the recursive partitioning analysis proposed by the Radiation Therapy Oncology Group. The median interval between radiotherapy and radiosurgery was 5 weeks (range 1-13). Treatment volumes ranged from 2.9 to 70.3 cc (median 15.0 cc). Prescribed radiosurgery doses varied from 8.0 to 12.5 Gy (median 10.0 Gy). Radiosurgery and control groups were well balanced with respect to prognostic factor distributions. Median actuarial survival time in radiosurgery and control groups was 21.4 months and 11.6 months, respectively (p = 0.0254). Among patients with KPS > 80, median survival time was 11.0 months and 53.9 months in the control and radiosurgery groups, respectively (p = 0.0103). Radiosurgery was the single factor correlated with survival on Cox model analysis (p = 0.0362) and was associated with a 2.76 relative reduction in the risk of cancer death (95% confidence interval (CI) 1.07-7.13). Our results suggest that radiosurgery may confer a survival advantage for patients in RPA classes III-VI, especially for those with Karnofsky performance status >80. The definitive role of radiosurgical boost for patients with high-grade gliomas awaits the results of randomized trials.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1023/A:1015757322379</identifier><identifier>PMID: 12125977</identifier><identifier>CODEN: JNODD2</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Brain Neoplasms - mortality ; Brain Neoplasms - pathology ; Brain Neoplasms - surgery ; Disease-Free Survival ; Follow-Up Studies ; Glioma - mortality ; Glioma - pathology ; Glioma - surgery ; Humans ; Medical sciences ; Middle Aged ; Neurology ; Radiosurgery ; Survival Analysis ; Time Factors ; Treatment Outcome ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Journal of neuro-oncology, 2002-04, Vol.57 (2), p.151-160</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Apr 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c310t-d44e2dec97079535b2727d36d31aa98038c5641965e2f8b3f24489c38c7162953</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13722048$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12125977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PRISCO, Flavio E</creatorcontrib><creatorcontrib>WELTMAN, Eduardo</creatorcontrib><creatorcontrib>HANRIOT, Rodrigo De</creatorcontrib><creatorcontrib>BRANDT, Reynaldo A</creatorcontrib><title>Radiosurgical boost for primary high-grade gliomas</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><description>The purpose of this study was to retrospectively evaluate the survival of patients with high-grade gliomas treated with external beam radiotherapy with or without radiosurgical boost. From July 1993 to April 1998, 32 patients were selected, 15 of which received radiosurgery. Inclusion criteria were age > 18 years, histological confirmation of high-grade glioma, primary tumor treatment with curative intent, unifocal tumor and supratentorial location. All patients were found to be in classes III-VI, according to the recursive partitioning analysis proposed by the Radiation Therapy Oncology Group. The median interval between radiotherapy and radiosurgery was 5 weeks (range 1-13). Treatment volumes ranged from 2.9 to 70.3 cc (median 15.0 cc). Prescribed radiosurgery doses varied from 8.0 to 12.5 Gy (median 10.0 Gy). Radiosurgery and control groups were well balanced with respect to prognostic factor distributions. Median actuarial survival time in radiosurgery and control groups was 21.4 months and 11.6 months, respectively (p = 0.0254). Among patients with KPS > 80, median survival time was 11.0 months and 53.9 months in the control and radiosurgery groups, respectively (p = 0.0103). Radiosurgery was the single factor correlated with survival on Cox model analysis (p = 0.0362) and was associated with a 2.76 relative reduction in the risk of cancer death (95% confidence interval (CI) 1.07-7.13). Our results suggest that radiosurgery may confer a survival advantage for patients in RPA classes III-VI, especially for those with Karnofsky performance status >80. The definitive role of radiosurgical boost for patients with high-grade gliomas awaits the results of randomized trials.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - surgery</subject><subject>Disease-Free Survival</subject><subject>Follow-Up Studies</subject><subject>Glioma - mortality</subject><subject>Glioma - pathology</subject><subject>Glioma - surgery</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Radiosurgery</subject><subject>Survival Analysis</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpd0N1LwzAQAPAgipvTZ9-kCPpWTe6SXuPbGH7BQBAF30rapl1Ht8xkffC_N2BF8Om443fH3TF2LviN4IC38zvBhSJFCICkD9g0ZpgSEh6yKRcZpUrLjwk7CWHNOZeE4phNBAhQmmjK4NXUnQuDb7vK9EnpXNgnjfPJzncb47-SVdeu0tab2iZt37mNCafsqDF9sGdjnLH3h_u3xVO6fHl8XsyXaYWC79NaSgu1rTRx0gpVCQRUY1ajMEbnHPNKZVLoTFlo8hIbkDLXVSyTyCB2zNj1z9ydd5-DDfti04XK9r3ZWjeEgoQG4lJHePkPrt3gt3G3AoRWlHEFEV2MaCg3ti7G-4rfV0RwNQIT4isab7ZVF_4cEgCXOX4D96dqKw</recordid><startdate>20020401</startdate><enddate>20020401</enddate><creator>PRISCO, Flavio E</creator><creator>WELTMAN, Eduardo</creator><creator>HANRIOT, Rodrigo De</creator><creator>BRANDT, Reynaldo A</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20020401</creationdate><title>Radiosurgical boost for primary high-grade gliomas</title><author>PRISCO, Flavio E ; WELTMAN, Eduardo ; HANRIOT, Rodrigo De ; BRANDT, Reynaldo A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-d44e2dec97079535b2727d36d31aa98038c5641965e2f8b3f24489c38c7162953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - surgery</topic><topic>Disease-Free Survival</topic><topic>Follow-Up Studies</topic><topic>Glioma - mortality</topic><topic>Glioma - pathology</topic><topic>Glioma - surgery</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Radiosurgery</topic><topic>Survival Analysis</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PRISCO, Flavio E</creatorcontrib><creatorcontrib>WELTMAN, Eduardo</creatorcontrib><creatorcontrib>HANRIOT, Rodrigo De</creatorcontrib><creatorcontrib>BRANDT, Reynaldo A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PRISCO, Flavio E</au><au>WELTMAN, Eduardo</au><au>HANRIOT, Rodrigo De</au><au>BRANDT, Reynaldo A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiosurgical boost for primary high-grade gliomas</atitle><jtitle>Journal of neuro-oncology</jtitle><addtitle>J Neurooncol</addtitle><date>2002-04-01</date><risdate>2002</risdate><volume>57</volume><issue>2</issue><spage>151</spage><epage>160</epage><pages>151-160</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><coden>JNODD2</coden><abstract>The purpose of this study was to retrospectively evaluate the survival of patients with high-grade gliomas treated with external beam radiotherapy with or without radiosurgical boost. From July 1993 to April 1998, 32 patients were selected, 15 of which received radiosurgery. Inclusion criteria were age > 18 years, histological confirmation of high-grade glioma, primary tumor treatment with curative intent, unifocal tumor and supratentorial location. All patients were found to be in classes III-VI, according to the recursive partitioning analysis proposed by the Radiation Therapy Oncology Group. The median interval between radiotherapy and radiosurgery was 5 weeks (range 1-13). Treatment volumes ranged from 2.9 to 70.3 cc (median 15.0 cc). Prescribed radiosurgery doses varied from 8.0 to 12.5 Gy (median 10.0 Gy). Radiosurgery and control groups were well balanced with respect to prognostic factor distributions. Median actuarial survival time in radiosurgery and control groups was 21.4 months and 11.6 months, respectively (p = 0.0254). Among patients with KPS > 80, median survival time was 11.0 months and 53.9 months in the control and radiosurgery groups, respectively (p = 0.0103). Radiosurgery was the single factor correlated with survival on Cox model analysis (p = 0.0362) and was associated with a 2.76 relative reduction in the risk of cancer death (95% confidence interval (CI) 1.07-7.13). Our results suggest that radiosurgery may confer a survival advantage for patients in RPA classes III-VI, especially for those with Karnofsky performance status >80. The definitive role of radiosurgical boost for patients with high-grade gliomas awaits the results of randomized trials.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>12125977</pmid><doi>10.1023/A:1015757322379</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-594X |
ispartof | Journal of neuro-oncology, 2002-04, Vol.57 (2), p.151-160 |
issn | 0167-594X 1573-7373 |
language | eng |
recordid | cdi_proquest_miscellaneous_71927049 |
source | MEDLINE; SpringerLink Journals |
subjects | Adult Aged Biological and medical sciences Brain Neoplasms - mortality Brain Neoplasms - pathology Brain Neoplasms - surgery Disease-Free Survival Follow-Up Studies Glioma - mortality Glioma - pathology Glioma - surgery Humans Medical sciences Middle Aged Neurology Radiosurgery Survival Analysis Time Factors Treatment Outcome Tumors of the nervous system. Phacomatoses |
title | Radiosurgical boost for primary high-grade gliomas |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T11%3A59%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiosurgical%20boost%20for%20primary%20high-grade%20gliomas&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=PRISCO,%20Flavio%20E&rft.date=2002-04-01&rft.volume=57&rft.issue=2&rft.spage=151&rft.epage=160&rft.pages=151-160&rft.issn=0167-594X&rft.eissn=1573-7373&rft.coden=JNODD2&rft_id=info:doi/10.1023/A:1015757322379&rft_dat=%3Cproquest_pubme%3E390347881%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219576052&rft_id=info:pmid/12125977&rfr_iscdi=true |